Orthofix Medical (NASDAQ:OFIX) Major Shareholder Juniper Investment Company, Ll Buys 14,803 Shares of Stock

Orthofix Medical Inc. (NASDAQ:OFIX) major shareholder Juniper Investment Company, Ll purchased 14,803 shares of the stock in a transaction that occurred on Wednesday, November 11th. The stock was acquired at an average cost of $7.04 per share, for a total transaction of $104,213.12. Following the completion of the acquisition, the insider owned 4,461,019 shares in the company, valued at $31,405,573.76. This represents a 0.33% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Juniper Investment Company, Ll also recently made the following trade(s):

• On Monday, November 9th, Juniper Investment Company, Ll purchased 675,000 shares of Orthofix Medical stock. The stock was acquired at an average price of $7.41 per share, with a total value of $5,001,750.00.

Orthofix Medical Trading Down 3.3%

OFIX stock opened at $6.94 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.11 and a quick ratio of 1.67. Orthofix Medical Inc. has a 1-year low of $6.52 and a 1-year high of $16.42. The business has a 50 day simple moving average of $9.12 and a two-hundred day simple moving average of $10.86. The company has a market capitalization of $282.67 million, a price-to-earnings ratio of -6.20 and a beta of 0.66.

Orthofix Medical (NASDAQ:OFIX) last released its quarterly earnings data on Monday, November 9th. The medical device company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.11. Orthofix Medical had a negative net margin of 5.39% and a negative return on equity of 10.32%. The firm had revenue of $207.86 million for the quarter, compared to analysts’ expectations of $210.52 million. Research analysts anticipate that Orthofix Medical Inc. will post -1.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of OFIX. State of Wyoming raised its stake in Orthofix Medical by 12.2% during the first quarter. State of Wyoming now owns 14,873 shares of the medical device company’s stock valued at $171,000 after purchasing an additional 1,617 shares in the last quarter. Parallel Advisors LLC lifted its position in Orthofix Medical by 2,434.1% during the third quarter. Parallel Advisors LLC now owns 3,269 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 3,140 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in Orthofix Medical during the second quarter valued at $30,000. Legal & General Group Plc purchased a new position in shares of Orthofix Medical in the 2nd quarter worth $37,000. Finally, Vise Technologies Inc. purchased a new position in shares of Orthofix Medical in the 3rd quarter worth $96,000. 89.76% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

OFIX has been the topic of several research analyst reports. Weiss Ratings cut shares of Orthofix Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, November 3rd. Canaccord Genuity Group cut their price objective on Orthofix Medical from $18.00 to $13.00 and set a “buy” rating for the company in a research report on Monday, August 10th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Orthofix Medical in a report on Tuesday. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $14.75.

About Orthofix Medical

Orthofix Medical Inc. develops and markets medical technologies for spine and orthopedic care. Its products include spinal implants and biologics, bone growth stimulation systems, and solutions used in fracture treatment and limb reconstruction. The company serves hospitals, surgeons, and other health care providers through its Orthofix and SeaSpine businesses. Its offerings span surgical products as well as noninvasive and specialized orthopedic treatments. Orthofix and SeaSpine completed a merger in 2023, combining their spine and orthopedic product portfolios.